The National Cancer Institute is launching a Phase 2 trial matching patients with specific mutations to drugs tailored to those genetic changes.
BRCA1 is a tumor-suppressor gene linked to familial breast and ovarian cancers. In the July 21 Cell, Bochar et al. find that the predominant BRCA1-containing complex in human cells is the SWI/SNF-related chromatin remodeling complex (Cell 2000, 102:257-265). This may explain the multitude of properties that have been ascribed to BRCA1, including effects on transcription, DNA repair, and cell-cycle checkpoints. Mutations in SNF5, another subunit of the SWI/SNF complex, have been shown to result i
July 31, 2000|